Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	FGFR2 N550K
Gene Variant Detail	FGFR2 N550K (gain of function)
Relevant Treatment Approaches	FGFR Inhibitor (Pan) FGFR2 Inhibitor

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 18 of 18 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FGFR2 N550K	endometrial cancer	predicted - sensitive	FGFR2 Inhibitor	TYRA-200	Preclinical - Cell line xenograft	Actionable	In a preclinical study, TYRA-200 demonstrated activity in an endometrial cancer cell line harboring FGFR2 N550K in culture and treatment resulted in 80% tumor regression in a cell line xenograft model (Eur J Cancer 2022 Vol 174, Supp 1:S16).	detail...
FGFR2 N550K	Advanced Solid Tumor	sensitive	FGFR Inhibitor (Pan)	PRN1371	Preclinical - Cell culture	Actionable	In a preclinical study, PRN1371 inhibited proliferation of transformed cells over expressing FGFR2 N550K in culture (PMID: 28978721).	28978721
FGFR2 N550K	endometrial cancer	predicted - sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, endometrial cells harboring Fgfr2 N550K were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).	26294741
FGFR2 N550K	endometrial cancer	sensitive	FGFR2 Inhibitor	ABT-737 + Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 N550K demonstrated increased cell death following treatment with AZD4547 and ABT-737 combination compared to either agent alone in culture (PMID: 30537101).	30537101
FGFR2 N550K	endometrial cancer	sensitive	FGFR Inhibitor (Pan)	ABT-737 + Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 N550K demonstrated increased cell death following treatment with Truseltiq (infigratinib) and ABT-737 combination compared to either agent alone in culture (PMID: 30537101).	30537101
FGFR2 N550K	endometrial cancer	sensitive		ABT-737 + PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, an endometrial cancer cell line harboring FGFR2 N550K demonstrated increased cell death following treatment with PD173074 and ABT-737 combination compared to either agent alone in culture (PMID: 30537101).	30537101
FGFR2 N550K	endometrial cancer	predicted - sensitive		PD173074	Preclinical - Cell culture	Actionable	In a preclinical study, PD173074 treatment induced cell death in an endometrial cancer cell line harboring FGFR2 N550K in culture (PMID: 30537101).	30537101
FGFR2 N550K	endometrial cancer	predicted - sensitive	FGFR Inhibitor (Pan)	Infigratinib	Preclinical - Cell culture	Actionable	In a preclinical study, Truseltiq (infigratinib) treatment induced cell death in an endometrial cancer cell line harboring FGFR2 N550K in culture (PMID: 30537101).	30537101
FGFR2 N550K	endometrial cancer	predicted - sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 treatment induced cell death in an endometrial cancer cell line harboring FGFR2 N550K in culture (PMID: 30537101).	30537101
FGFR2 N550K	estrogen-receptor positive breast cancer	sensitive	FGFR2 Inhibitor	Fexagratinib	Preclinical - Cell culture	Actionable	In a preclinical study, AZD4547 treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 N550K in culture (PMID: 32723837).	32723837
FGFR2 N550K	estrogen-receptor positive breast cancer	sensitive	FGFR Inhibitor (Pan)	FIIN-2	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-2 treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 N550K in culture (PMID: 32723837).	32723837
FGFR2 N550K	estrogen-receptor positive breast cancer	sensitive	FGFR Inhibitor (Pan)	FIIN-3	Preclinical - Cell culture	Actionable	In a preclinical study, FIIN-3 treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 N550K in culture (PMID: 32723837).	32723837
FGFR2 N550K	estrogen-receptor positive breast cancer	sensitive		Trametinib	Preclinical - Cell culture	Actionable	In a preclinical study, Mekinist (trametinib) treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 N550K in culture (PMID: 32723837).	32723837
FGFR2 N550K	estrogen-receptor positive breast cancer	sensitive		SHP099	Preclinical - Cell culture	Actionable	In a preclinical study, SHP099 treatment decreased viability of ESR1-positive breast cancer cells expressing FGFR2 N550K in culture (PMID: 32723837).	32723837
FGFR2 N550K	Advanced Solid Tumor	predicted - sensitive	FGFR2 Inhibitor	TYRA-200	Preclinical - Cell culture	Actionable	In a preclinical study, TYRA-200 inhibited FGFR2 N550K in an in vitro assay and demonstrated activity in cells expressing FGFR2 N550K in culture (Eur J Cancer 2022 Vol 174, Supp 1:S16).	detail...
FGFR2 N550K	Advanced Solid Tumor	resistant	FGFR Inhibitor (Pan)	Dovitinib	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).	23908597
FGFR2 N550K	Advanced Solid Tumor	sensitive	FGFR Inhibitor (Pan)	Ponatinib	Preclinical	Actionable	In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550K (PMID: 23908597).	23908597
FGFR2 N550K	Advanced Solid Tumor	resistant		PD173074	Preclinical	Actionable	In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to PD173074 (PMID: 23908597).	23908597

Showing 1 to 18 of 18 entries

Filter rows: